{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Medication+Adjustment", "query": { "intervention": "Medication Adjustment" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 520, "total_pages": 52, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Medication+Adjustment&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T23:06:18.561Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00078559", "title": "Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Kidney Transplantation", "Kidney Disease" ], "interventions": [ { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Kidney transplant", "type": "PROCEDURE" }, { "name": "Methylprednisolone (or equivalent)", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Trimethoprim (TMP)/Sulfa (Bactrim, Septra)", "type": "DRUG" }, { "name": "Valgancyclovir", "type": "DRUG" }, { "name": "Acyclovir", "type": "DRUG" }, { "name": "Pentamidine", "type": "DRUG" }, { "name": "Clotrimazole", "type": "DRUG" }, { "name": "Nystatin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 10, "start_date": "2003-11", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2018-06-29", "last_synced_at": "2026-09-03T23:06:18.561Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00078559" }, { "nct_id": "NCT01768559", "title": "Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Lixisenatide (AVE0010)", "type": "DRUG" }, { "name": "Insulin glulisine QD", "type": "DRUG" }, { "name": "Insulin glulisine TID", "type": "DRUG" }, { "name": "Insulin Glargine (Mandatory background drug)", "type": "DRUG" }, { "name": "Metformin (Background drug)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 894, "start_date": "2013-01", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2017-01-04", "last_synced_at": "2026-09-03T23:06:18.561Z", "location_count": 46, "location_summary": "Sun City, Arizona • Tempe, Arizona • Little Rock, Arkansas + 41 more", "locations": [ { "city": "Sun City", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Mesa", "state": "California" }, { "city": "Mission Viejo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01768559" }, { "nct_id": "NCT00221403", "title": "Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bipolar Disorder" ], "interventions": [ { "name": "Risperidone oral solution", "type": "DRUG" }, { "name": "Valproate Oral Solution", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "7 Years", "sex": "ALL", "summary": "3 Years to 7 Years" }, "enrollment_count": 46, "start_date": "2004-09", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2020-10-20", "last_synced_at": "2026-09-03T23:06:18.561Z", "location_count": 2, "location_summary": "Cincinnati, Ohio • Milwaukee, Wisconsin", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00221403" }, { "nct_id": "NCT00763490", "title": "Trial Of Double Umbilical Cord Blood Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematological Malignancies" ], "interventions": [ { "name": "Full intensity, double umbilical cord, stem cell transplant", "type": "PROCEDURE" }, { "name": "Flu/Bu4 conditioning regimen", "type": "DRUG" }, { "name": "Total Lymphoid Irradiation (TLI)", "type": "RADIATION" }, { "name": "Graft versus Host Disease prevention (GVHD prophylaxis)", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "65 Years", "sex": "ALL", "summary": "Up to 65 Years" }, "enrollment_count": 20, "start_date": "2008-12", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2016-12-23", "last_synced_at": "2026-09-03T23:06:18.561Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00763490" }, { "nct_id": "NCT07169279", "title": "Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Achondroplasia" ], "interventions": [ { "name": "Infigratinib is provided as a single dose of minitablets for oral administration", "type": "DRUG" }, { "name": "Infigratinib is provided as sprinkle capsules for daily oral administration", "type": "DRUG" }, { "name": "Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QED Therapeutics, a BridgeBio company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "32 Months", "sex": "ALL", "summary": "0 Years to 32 Months" }, "enrollment_count": 77, "start_date": "2025-11-19", "completion_date": "2032-03", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-09-03T23:06:18.561Z", "location_count": 3, "location_summary": "Oakland, California • Baltimore, Maryland • Madison, Wisconsin", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT07169279" }, { "nct_id": "NCT02631876", "title": "A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epithelial Ovarian Cancer", "Primary Peritoneal Carcinoma", "Fallopian Tube Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "Mirvetuximab soravtansine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pegylated liposomal doxorubicin", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunoGen, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 366, "start_date": "2016-03-02", "completion_date": "2020-01", "has_results": true, "last_update_posted_date": "2020-10-14", "last_synced_at": "2026-09-03T23:06:18.561Z", "location_count": 53, "location_summary": "Birmingham, Alabama • Tempe, Arizona • Tucson, Arizona + 44 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02631876" }, { "nct_id": "NCT07628972", "title": "Quercetin Dyskeratosis Congenita (DC)/Telomere Biology Disorders (TBD)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Dyskeratosis Congenita", "Telomere Disease" ], "interventions": [ { "name": "Quercetin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 12, "start_date": "2026-05-29", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-09-03T23:06:18.561Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07628972" }, { "nct_id": "NCT00071799", "title": "A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Physician Choice", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 358, "start_date": "2003-11-01", "completion_date": "2007-07-01", "has_results": true, "last_update_posted_date": "2019-10-29", "last_synced_at": "2026-09-03T23:06:18.561Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Indianapolis, Indiana • St Louis, Missouri + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00071799" }, { "nct_id": "NCT03224507", "title": "Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "KRdD followed by auto-HCT", "type": "DRUG" }, { "name": "KRdD only", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 123, "start_date": "2018-03-14", "completion_date": "2023-06-30", "has_results": true, "last_update_posted_date": "2023-11-24", "last_synced_at": "2026-09-03T23:06:18.561Z", "location_count": 4, "location_summary": "Birmingham, Alabama • Portland, Oregon • Nashville, Tennessee + 1 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Portland", "state": "Oregon" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03224507" }, { "nct_id": "NCT00023244", "title": "Steroid Withdrawal in Pediatric Kidney Transplant Recipients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "End-Stage Renal Disease" ], "interventions": [ { "name": "Basiliximab", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Bactrim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "20 Years", "sex": "ALL", "summary": "1 Day to 20 Years" }, "enrollment_count": 274, "start_date": "2001-01", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2016-10-21", "last_synced_at": "2026-09-03T23:06:18.561Z", "location_count": 18, "location_summary": "Birmingham, Alabama • San Diego, California • Aurora, Colorado + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00023244" } ] }